The U.S. prostate cancer nuclear medicine diagnostics market size was valued at USD 172.2 million in 2018 and is estimated to expand at a CAGR of 10.7%during the forecast period. Rising incidence of prostate cancer is expected to impel the demand for early and accurate diagnosis of the disease.